SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention after 24-month HOPE-3 extension data showed slower upper-limb deterioration among Duchenne muscular dystrophy patients treated with deramiocel, bolstering the case ahead of an FDA decision. Bulls view the results as supportive, while skeptics say they may not resolve the FDAs prior statistical concerns; short-squeeze speculation is prominent but unconfirmed.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Fords prolonged decline and repeated failures to hold support dominate the discussion, with traders debating whether oversold conditions could prompt a bounce or further losses lie ahead. Some also point to tariff uncertainty, production and supply-chain issues, and competition as ongoing concerns weighing on sentiment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal Q4 earnings report is the focus, with traders watching whether AI-driven HBM and DRAM demand can sustain strong pricing, margins, and the memory upcycle. Many expect a strong quarter, but debate whether that is already priced in; guidance on the cycles durability is seen as the key to the market reaction, with sell-the-news concerns also prominent.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs strong move and elevated trading volume have fueled breakout and short-squeeze speculation, with traders debating whether the rally can hold or will fade without a confirmed announcement. Some point to anticipated Anktiva trial data and an FDA label-expansion decision as potential catalysts, but claims of an imminent leak or squeeze remain speculative.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is under pressure as long-term Treasury yields surge, with traders pointing to expectations for rates to stay higher, persistent inflation and concerns about federal debt; some also cite energy-market and geopolitical risks. The community is divided between expecting further bond losses and viewing the selloff as an oversold buying opportunity.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

A Delaware court ruled that two United Therapeutics patent claims covering treatment of PH-ILD are valid and infringed by Liquidias YUTREPIA, prompting a steep selloff and trading halt. Traders are weighing uncertain remediesincluding possible label or availability restrictionsagainst Liquidias stated plans to appeal, with debate over whether the ruling threatens the business or is an overreaction.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels CAN-2409 prostate-cancer program is drawing attention for PrTK05 biomarker findings indicating T-cell activation and the companys stated plan to submit a BLA in Q4 2026. Traders see the data as supportive of the treatments mechanism, while others question the limited biomarker sample and raise concerns about study changes, manufacturing readiness, and a possible filing delay; some are also frustrated that the share price has weakened despite the encouraging results.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas raised revenue outlook and growth in its AI-driven marketing platform are fueling bullish attention, with traders also anticipating announcements at Zeta Live and the next earnings report. Sentiment is mostly optimistic, though some traders cite dilution concerns and caution after recent volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks steep selloff is being attributed to slowing revenue growth, weak guidance, and concerns about ad spending and competition from Amazon and other platforms. Traders are split between expecting more downside and arguing the decline is overdone given the companys cash and profitability, while many criticize CEO Jeff Green and his incentive package.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA discussion centers on rising Treasury yields and expectations of further Fed tightening weighing on equities, alongside concerns about oil-driven inflation and weak market breadth. Traders debate whether softer PCE data can ease rate fears, while bearish views on valuations and AI risks compete with dip-buying optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DLCR Promised $7 Feb 2023. I&#39;m in. Even if it hits .70¢ I&#39;m in.

Tim Olson

StockTwits Web

Kibush Capital Corp

 Promised $7 Feb 2023. I'm in. Even if it hits .70¢ I'm in.

Amaeze Amadi

@NIVO January readings of the $864.297 52wk High reads $66.. of 1:200 ratio. In $6-$66 range under 10,000 prognosis

 January readings of the $864.297 52wk High reads $66.. of 1:200 ratio. In $6-$66 range under 10,000 prognosis

@Madefours gonna need to be pink compliant before that is even a reality. cant trade unless in expert market.

 gonna need to be pink compliant before that is even a reality. cant trade unless in expert market.

@NIVO $DLCR is a Gold miners stock. Heard of that sorry $JDST 🤣😔. $DLCR will be big in the next 45days approx $7

Direxion Daily Junior Gold Miners Index Bear 2X Shares

 is a Gold miners stock. Heard of that sorry 

 will be big in the next 45days approx $7

@Madefours we need 737 million revenue by then for a dollar/share. thats 368.5 million to get to .50/share. you&#39;re just trollin man. and for the 10th time you need to be pink compliant with all paperwork before we can even trade unless in expert market. im not replying any further to this until Warren Shepard actually does something.

MVSTACKS

 we need 737 million revenue by then for a dollar/share. thats 368.5 million to get to .50/share. you're just trollin man. and for the 10th time you need to be pink compliant with all paperwork before we can even trade unless in expert market. im not replying any further to this until Warren Shepard actually does something.

@NIVO $DLCR is some how the nearest OTC stock trend giving the nearest pay date in Jan or Feb coming soon for junior gold miners stocks. No troll with a title that always looks all alone. $DLCR will hit $7 from today&#39;s price in zero ten thousandths price margin .ooo3¢ -$7. Put a &#39;litl bit on it and hold until Feb ends . You&#39;ll be paid in full. I promise that. 💰💵☃️🎄🎉

 is some how the nearest OTC stock trend giving the nearest pay date in Jan or Feb coming soon for junior gold miners stocks. No troll with a title that always looks all alone. 

 will hit $7 from today's price in zero ten thousandths price margin .ooo3¢ -$7. Put a 'litl bit on it and hold until Feb ends . You'll be paid in full. I promise that. 💰💵☃️🎄🎉

@NIVO I&#39;m looktat sources and reading the future trend lines. $DLCR may push back a whole entire year. Anything dealing with gold mining ⛏️ stock I will cancel trades for good.

 I'm looktat sources and reading the future trend lines. 

 may push back a whole entire year. Anything dealing with gold mining ⛏️ stock I will cancel trades for good.